Stoke Therapeutics, Inc. (STOK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$29.92-0.43%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Achieve revenue of at least $10.6 million in 2025: Q2 FY2026 rev $9.3M vs $10.6M target.
Stoke is advancing its Phase 3 study for zorevunersen. It plans to finish enrolling 150 patients by Q2 2026. The company expects revenue of at least $10.6 million in 2025. It has funding from Biogen to support operations through 2028.
Stoke is still losing money and not yet profitable. Revenue growth is uncertain and below expectations. Delays in clinical trials could hurt progress and funding.
The market expects about 28% revenue growth next year. Our fair value is near the current price, reflecting this growth and risks.
Breaks if: Funding runs out before 2028
Breaks if: Enrollment not completed by end of Q2 2026
Revenue falls below $10.6 million in 2025
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious, given the mixed signals from management priorities and recent financial results.
The market appears to price in a significant expectations gap, suggesting that STOK is seen as having high optionality despite its current loss-making status. Valuation is elevated compared to peers, indicating that investors may be anticipating a turnaround.
Fundamentals may remain weak in the near term, as recent performance has been below industry standards. However, management has shown a stable cash position, which could support operations while awaiting future developments.
The long-term thesis hinges on the successful completion of key studies and pipeline advancements, as well as broader sector performance. Any negative guidance or economic downturn could further pressure the stock.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company completed Phase 3 study enrollment. This supports the outlook for zorevunersen. However, the latest earnings report missed expectations. This raises concerns about future performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, STOK's performance will depend on its ability to execute on its clinical milestones and manage risks effectively. Not investment advice.